Intravenous levosimendan treatment is cost-effective compared with dobutamine in severe low-output heart failure: an analysis based on the international LIDO trial-Reference-Cited by-同舟云学术

Intravenous levosimendan treatment is cost-effective compared with dobutamine in severe low-output heart failure: an analysis based on the international LIDO trial

Published:2003-01 Issue:1 Volume:5 Page:101-108
ISSN:1388-9842
Container-title:European Journal of Heart Failure
language:en
Short-container-title:European Journal of Heart Failure

Author:

Cleland J.G.F.¹,Takala A.²,Apajasalo M.²,Zethraeus N.³,Kobelt G.⁴

Affiliation:

1. Department of Cardiology, Castle Hill Hospital, Castle Road, Cottingham; University of Hull; Kingston upon Hull HU16 5JQ UK

2. Orion Pharma Research Centre; Espoo Finland

3. Centre for Health Economics; Stockholm School of Economics; Stockholm Sweden

4. Health Dynamics International; London UK

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine

Reference29 articles.

1. Heart failure: a medical hydra;Cleland;Lancet,1998

2. The heart failure epidemic: exactly how big is it;Cleland;Eur Heart J,2001

3. Survival of patients with a new diagnosis of heart failure: a population based study;Cowie;Heart,2000

4. Is the prognosis of heart failure improving;Khand;J Am Coll Cardiol,2000

5. Hospitalization of patients with heart failure. A population-based study;Cowie;Eur Heart J,2002

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Preconditioning with levosimendan reduces postoperative low cardiac output in moderate-severe systolic dysfunction patients who will undergo elective coronary artery bypass graft surgery: a cost-effective strategy;Journal of Cardiothoracic Surgery;2020-05-24

2. Levosimendan in Cardiac Surgery: Evaluating the Evidence;Journal of Cardiothoracic and Vascular Anesthesia;2019-04

3. Evaluating Cost-Effectiveness Models for Pharmacologic Interventions in Adults with Heart Failure: A Systematic Literature Review;PharmacoEconomics;2018-12-31

4. Cost-benefits of incorporating levosimendan into cardiac surgery practice: German base case;Journal of Medical Economics;2016-01-08

5. Pharmaco-economics of levosimendan in cardiology: A European perspective;International Journal of Cardiology;2015-11